Welcome to our dedicated page for VanEck Green Infrastructure ETF news (Ticker: RNEW), a resource for investors and traders seeking the latest updates and insights on VanEck Green Infrastructure ETF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VanEck Green Infrastructure ETF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VanEck Green Infrastructure ETF's position in the market.
Ecofin announced its Ecofin Global Renewables Infrastructure UCITS Fund has been classified as Article 9 under the EU's Sustainable Finance Disclosure Regulation (SFDR), effective December 1, 2022. This designation signifies compliance with the highest sustainability criteria. Ecofin aims for at least 90% of the fund's portfolio to comprise sustainable investments, emphasizing low-carbon power generation and companies transitioning from fossil fuels to renewable energy. The Ecofin U.S. Renewables Infrastructure Trust (RNEW) also meets the Article 9 standards and holds the London Stock Exchange's Green Economy Mark.
Suneva Medical has received Canadian regulatory approval for its Dermapose® all-in-one fat sizing syringe, enhancing its presence in the regenerative aesthetics market. Additionally, the U.S. FDA granted 510(k) clearance for the larger 30 mL Amplifine PRP Gel Tube, allowing for greater efficiency in regenerative treatments. These advancements highlight Suneva's commitment to providing innovative, minimally invasive solutions in aesthetic procedures, catering to the growing demand for natural-looking treatment options.
Suneva Medical announced FDA acceptance of updates to the Plasma IQ label, notably removing the eye contraindication, enhancing treatment options around the eye. This update supports the company’s merger with Viveon Health Acquisition Corp. (VHAQ), aiming for increased market access. Plasma IQ is the first handheld FDA-cleared plasma energy device for skin lesion treatment. The merger is set to allow shares to trade under the symbol RNEW upon completion. Suneva, located in San Diego, continues to innovate in regenerative aesthetics, focusing on patient solutions.
Suneva Medical, an innovative firm in regenerative aesthetics, has announced a merger agreement with Viveon Health Acquisition Corp (NYSE: VHAQ). The merger, expected to close in the first half of 2022, aims to leverage Suneva's patented products to meet the growing demand in the $11 billion regenerative aesthetics market. The pro forma equity valuation of the combined company is projected at $511 million, with potential share earn-outs tied to performance metrics. Both companies emphasize enhancing shareholder value and expanding market reach through this partnership.
FAQ
What is the current stock price of VanEck Green Infrastructure ETF (RNEW)?
